As travelers pivot from overcrowded hot spots, many are discovering the quietly authentic charms of Syros, home to some of ...

A mysterious Kia prototype has been turning heads on Korean roads after a sharp-eyed member of the Naver Electric Vehicle ...

BHPian highwaypatrol recently shared this with other enthusiasts:20 Days of Ownership | 500 KMs CompletedHello ...

Kia India had the Sonet as its best-selling model in Sept 2025 marking a healthy MoM increase while Carens sales grew both ...

Kia India is offering attractive discounts on three of its SUVs and two MPVs this month. With the recently announced revised GST rates having drastically brought down prices on several models, this ...

Kia is offering benefits worth up to Rs 1.60 lakh on its popular car lineup in India. Here are the details you must check out ...

Kia India has expanded its extended warranty program to seven years for the Sonet, Syros, Carens, and Seltos, offering ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug ...

Syros Pharmaceuticals Inc SYRS revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate. The trial assessed tamibarotene in ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has entered into a ...

Syros Pharmaceuticals Inc received notice from Pfizer Inc PFE, as successor to Global Blood Therapeutics Inc, exercising its right to terminate the License and Collaboration Agreement dated December ...

Incyte has ended a five-year collaboration with Syros Pharmaceuticals after seven targets were identified for myeloproliferative neoplasms and none taken back to the lab for further development.